134 results on '"Perez-Mancera, Pedro A."'
Search Results
2. KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice
3. Mouse Models of Pancreatic Exocrine Cancer
4. Figure S7 from Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer
5. Supplementary Table S12 from Tissue-Specific Oncogenic Activity of KRASA146T
6. Supplementary Tables S14-S17 from Tissue-Specific Oncogenic Activity of KRASA146T
7. Data from Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer
8. Data from Tissue-Specific Oncogenic Activity of KRASA146T
9. Supplementary Figures S1-S18 from Tissue-Specific Oncogenic Activity of KRASA146T
10. Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer
11. Supplementary Table 3 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
12. Supplementary Table 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
13. Supplementary Table 4 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
14. Data from Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
15. Supplemental Methods from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
16. Supplementary Figure Legends, Supplementary Tables 1 and 2 and Supplementary Materials and Methods from Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
17. Supplementary Figures 1 through 9 from Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
18. Data from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
19. Supplementary Table 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
20. Supplementary Figure 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
21. Supplementary Figure 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
22. Abstract C084: Oncogenic KRAS signaling drives the activation of tissue-resident fibroblasts and is required to maintain CAF heterogeneity in pancreatic cancer
23. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
24. The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis
25. Abstract 3647: Oncogenic Kras drives cancer-associated fibroblast heterogeneity and substate changes in pancreatic cancer
26. What We Have Learned About Pancreatic Cancer From Mouse Models
27. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma
28. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma
29. A second site Kras(G12D) mutation that impairs PI3K binding rescues embryonic lethality, abrogates myeloproliferative disease, and delays lung tumorigenesis
30. A novel scaffold based hybrid multicellular model for pancreatic ductal adenocarcinoma – towards a better mimicry of the in vivo tumour microenvironment
31. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry
32. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
33. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia
34. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium
35. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
36. Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
37. Abstract A23: A second site KrasG12D mutation that impairs PI3K binding rescues embryonic lethality, abrogates myeloproliferative disease, and delays lung tumorigenesis
38. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer
39. PDAC-associated fibroblasts are less responsive to an anti-fibrotic stimulus and more responsive to a positive regulator of fibroblast activation than normal activated fibroblasts
40. Tissue-Specific Oncogenic Activity of KRASA146T
41. Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
42. Disease associated fibroblasts from various pancreatic disorders exhibit subtype specific genetic profile
43. The efficacy of brusatol as a chemotherapeutic agent in pancreatic cancer and its relevance to potential chemoresistance conferred by Nrf2
44. ON THE DEVELOPMENT OF A BIOINSPIRED, BIOMIMETIC PANCREATIC CANCER MODEL: ENGINEERING A HYBRID SCAFFOLD ASSISTED IN VITRO MULTICELLULAR MODEL OF PANCREATIC CANCER
45. Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
46. Identification of novel signalling pathways dysregulated in pancreatic cancer-associated fibroblasts
47. Abstract 798: Clonal analysis and clinical translation of pancreatic adenocarcinoma genomes.
48. Abstract A64: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.
49. Abstract SY08-01: Large-scale screens for cancer genes in the mouse
50. Erratum: Corrigendum: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.